We could not find any results for:
Make sure your spelling is correct or try broadening your search.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a select... aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. Show more
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), all...
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...
Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT™ study investi...
Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique anti-inflammatory mechanism. Role of NRP2 in immune system validated by ...
SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.43 | 27.3885350318 | 1.57 | 2.03 | 1.55 | 625275 | 1.78868734 | CS |
4 | -0.05 | -2.43902439024 | 2.05 | 2.1162 | 1.55 | 777730 | 1.81529178 | CS |
12 | 0.66 | 49.2537313433 | 1.34 | 2.1162 | 1.34 | 517826 | 1.76062218 | CS |
26 | 0.31 | 18.3431952663 | 1.69 | 2.1162 | 1.0801 | 389189 | 1.58049171 | CS |
52 | 0.04 | 2.04081632653 | 1.96 | 2.6999 | 1.0801 | 432458 | 1.8721372 | CS |
156 | -3.5 | -63.6363636364 | 5.5 | 13.1 | 1.0801 | 721439 | 7.05697489 | CS |
260 | -4.566 | -69.5400548279 | 6.566 | 13.1 | 1.0801 | 595732 | 6.60394089 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: 1-888-992-3836 | help@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |